Best Practice Guidance for Emerging Infectious Fever Preparedness

Abstract

Emerging infectious fevers continue to pose significant challenges to global health security, especially given the unpredictable nature of novel pathogens, varying clinical presentations, and the potential for rapid transmission. This review synthesizes current best practice guidance for preparedness and response to emerging infectious fevers, drawing from recent outbreaks, epidemiological trends, and evidence-based guidelines. Key focus areas include understanding disease burden, elucidating pathophysiological mechanisms, identifying high-risk populations, optimizing diagnostic approaches, evidence-based management, and integrating recent advances in therapeutics and public health strategies. Practical recommendations are offered to inform clinicians, hospital systems, and public health professionals in enhancing readiness and response capacity.

Introduction

Emerging infectious fevers, defined by rapid-onset pyrexia due to novel or re-emerging pathogens, represent a persistent threat to public health. The 21st century has witnessed several notable outbreaks, including SARS, MERS, Ebola, Zika, and most recently, COVID-19. These events have underscored the importance of robust preparedness strategies at individual, institutional, and policy levels. Preparedness involves not only early recognition and containment but also the capacity to adapt to evolving evidence and integrate multidisciplinary approaches. This article provides a comprehensive review of best practice guidance for emerging infectious fever preparedness, with a focus on clinical relevance and actionable insights for healthcare professionals.

Epidemiology / Disease Burden

The global burden of emerging infectious fevers is shaped by several factors, including ecological changes, globalization, climate variability, and increased human–animal interface. Surveillance data from the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) illustrate a rising trend in zoonotic spillovers and cross-border transmission. Outbreaks frequently originate in regions with high biodiversity and limited healthcare infrastructure. Morbidity and mortality rates vary by pathogen, with diseases like Ebola and Marburg virus demonstrating high case-fatality rates, while others such as Zika virus cause substantial morbidity due to neurological complications. The economic and societal impact of infectious fevers extends beyond direct health consequences, affecting workforce productivity, healthcare resource allocation, and global mobility.

Pathophysiology

Emerging infectious fevers typically result from viral, bacterial, or occasionally protozoal pathogens with mechanisms that disrupt host thermoregulation and induce systemic inflammatory responses. Host–pathogen interactions often involve evasion of innate immunity, dysregulated cytokine release ("cytokine storm"), and direct cytopathic effects. For example, filoviruses such as Ebola induce vascular endothelial dysfunction leading to hemorrhagic manifestations, while coronaviruses may trigger acute respiratory distress syndrome (ARDS) via alveolar damage and hyperinflammatory cascades. Understanding these mechanisms is crucial for targeted therapeutic interventions and risk stratification.

Risk Factors

Risk factors for acquiring and developing severe forms of emerging infectious fevers include occupational exposure (e.g., healthcare workers, laboratory personnel), travel to endemic areas, immunosuppression, extremes of age, and comorbidities such as diabetes and cardiovascular disease. Socioeconomic determinants, including limited access to healthcare, poor sanitation, and high population density, further amplify vulnerability. Genomic susceptibility and pre-existing immunity may also influence individual risk profiles, as observed in differential outcomes during the COVID-19 pandemic.

Clinical Features

The clinical presentation of emerging infectious fevers is often nonspecific at onset, with symptoms such as fever, malaise, myalgia, and headache. Disease progression may reveal pathogen-specific syndromes: hemorrhagic diathesis in viral hemorrhagic fevers, rash in arboviral infections, or severe respiratory compromise in novel influenza and coronaviruses. Rapid deterioration, multi-organ dysfunction, or neurological involvement are red flags necessitating urgent intervention. Accurate epidemiological history, including travel and exposure risk, is vital in differentiating infectious fevers from other acute febrile illnesses.

Diagnosis

Timely diagnosis requires a combination of clinical acumen and systematic laboratory evaluation. Molecular assays such as real-time PCR remain the gold standard for pathogen detection, offering high sensitivity and specificity. Point-of-care antigen testing can facilitate triage in resource-limited settings, though confirmatory testing is recommended. Serological assays aid in retrospective diagnosis and epidemiological surveillance. Imaging (e.g., chest radiography, CT) and laboratory markers (e.g., leukopenia, elevated transaminases, coagulopathy) provide supportive evidence and inform disease severity assessment. A syndromic approach, guided by local epidemiology and risk assessment, is essential for prompt isolation and containment.

Treatment & Management

Management of emerging infectious fevers is fundamentally supportive, emphasizing hemodynamic stabilization, oxygenation, and organ support as indicated. Specific antiviral or antibacterial therapies are limited but evolving; for example, remdesivir and monoclonal antibodies have demonstrated benefit in certain viral infections. Early initiation of empirical therapy may be warranted in severe presentations pending definitive diagnosis. Strict infection prevention and control (IPC) measures, including personal protective equipment (PPE), patient isolation, and environmental decontamination, are critical to prevent nosocomial transmission. Multidisciplinary care teams, including infectious disease specialists, intensivists, and public health professionals, optimize patient outcomes.

Recent Advances / Emerging Therapies

The landscape of therapeutics for emerging infectious fevers is rapidly evolving. Novel antiviral agents, immunomodulators, and adjunctive therapies are under investigation in clinical trials. mRNA vaccine platforms, demonstrated during the COVID-19 pandemic, offer rapid scalability and adaptability for future outbreaks. Point-of-care molecular diagnostics and digital surveillance technologies enhance early detection and real-time response. Artificial intelligence and big data analytics are increasingly leveraged for outbreak prediction and resource allocation. These advances underscore the need for adaptive clinical protocols and ongoing professional education.

Guideline Recommendations

International and national health authorities, including WHO, CDC, and the Infectious Diseases Society of America (IDSA), provide comprehensive guidelines for emerging infectious fever preparedness. Core recommendations include establishing surveillance and early warning systems, maintaining strategic stockpiles of PPE and essential medicines, and fostering rapid response teams. Routine simulation exercises, staff training, and up-to-date protocols for triage, isolation, and case management are emphasized. Hospitals should implement hierarchical IPC measures tailored to pathogen risk, and maintain communication channels with public health authorities. Ongoing review and adaptation of guidelines to reflect emerging evidence and local context is essential.

Conclusion

Preparedness for emerging infectious fevers necessitates a multifaceted, evidence-based approach encompassing surveillance, early recognition, robust IPC, and dynamic clinical management. Continued investment in research, healthcare infrastructure, and workforce training is imperative. Integration of novel diagnostics, therapeutics, and digital tools will further strengthen health system resilience. Healthcare providers play a pivotal role in identifying, managing, and containing emerging infectious threats, safeguarding both individual patients and broader communities. Adherence to best practice guidance and adaptive learning from recent outbreaks will be key to mitigating future risks.